NCT00623727 BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A Status TERMINATED Phase PHASE2
NCT00623480 Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment Status COMPLETED Phase PHASE3
NCT00623467 Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging Status COMPLETED Phase PHASE3
NCT00622479 Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia. Status TERMINATED Phase PHASE1
NCT00621673 Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A Status TERMINATED Phase PHASE4
NCT00619242 The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer Status TERMINATED Phase NA
NCT00617903 Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea Status COMPLETED Phase PHASE2
NCT00616564 Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma Status COMPLETED Phase PHASE2
NCT00613145 Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT00610194 Phase 1 Dose-escalation PK/PD Trial in Advanced Cancer Patients Status COMPLETED Phase PHASE1
NCT00609804 Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib Status COMPLETED Phase PHASE2
NCT00607854 Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007) Status COMPLETED Phase PHASE2
NCT00607438 A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer Status TERMINATED Phase PHASE2
NCT00606866 MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma Status COMPLETED Phase PHASE3
NCT00606125 Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors Status COMPLETED Phase PHASE1
NCT00601003 Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma Status COMPLETED Phase PHASE2